Information  X 
Enter a valid email address

Physiomics wins new deal with global pharma

By BFN News | 01:14 PM | Thursday 14 August, 2014

Oxford-based biology company Physiomics has signed a new contract with a global pharmaceutical company. The project will involve adapting the existing Virtual Tumour to model immunomodulatory agents, currently a significant focus of cancer research. The initial phase of the project will be focused on making pre-clinical predictions. If successful, the project may be extended to also adapt Virtual Tumour Clinical to immune therapies in cancer. The initial project will start immediately and will be completed by the end of the year. The project will be performed on a fee-for-service basis. At 1:14pm: (LON:PYC) Physiomics PLC share price was +0.03p at 0.19p Story provided by

a d v e r t i s e m e n t